Diagnostic criteria for enduring sexual dysfunction after treatment with antidepressants, finasteride and isotretinoin
| Autor: | Irwin Goldstein, Silvia Diviccaro, Silvia Giatti, Audrey S. Bahrick, Barbara D'Avanzo, Caroline F. Pukall, David Healy, Heiko Graf, Angelo Barbato, David Edmund Johannes Linden, Amy M. Pearlman, Barbara M. Chubak, Michał Lew-Starowicz, Mohit Khera, Stuart Shipko, Fiammetta Cosci, Omar Walid Muquebil Ali Al Shaban Rodríguez, Joanna Le Noury, Michael S. Irwig, Arianna Patacchini, Paddy K.C. Janssen, Rudy Schreiber, Celine Lüning, Maarten Bak, Jalesh N. Panicker, Dee Mangin, Ahad Waraich, Manoj Therayil Kumar, Barbora Vašečková, Rachel Rubin, Yacov Reisman, Emmanuele A. Jannini, Wayne J.G. Hellstrom, Roberto Cosimo Melcangi, Sanjana Raj, Rocco Salvatore Calabrò, Antonei B. Csoka |
|---|---|
| Přispěvatelé: | RS: MHeNs - R3 - Neuroscience, Psychiatrie & Neuropsychologie, RS: MHeNs - R2 - Mental Health, MUMC+: DA KFT Medische Staf (9), Clinical Pharmacy, RS: MHeNs - R1 - Cognitive Neuropsychiatry and Clinical Neuroscience, Section Psychopharmacology, RS: FPN NPPP II |
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: |
Male
Adolescent Serotonin reuptake inhibitor Irritability Asexuality Arousal Persistent genital arousal disorder DOUBLE-BLIND PERSISTENT selective serotonin reuptake inhibitors medicine Humans Child business.industry Health Policy Public Health Environmental and Occupational Health isotretinoin General Medicine GENITAL AROUSAL DISORDER medicine.disease EFFICACY Antidepressive Agents finasteride Sexual Dysfunction Physiological Sexual desire Post-SSRI sexual dysfunction Sexual dysfunction Erectile dysfunction PREMATURE EJACULATION CITALOPRAM antidepressants SAFETY medicine.symptom business Clinical psychology |
| Zdroj: | International Journal of Risk and Safety in Medicine, 33(1), 65-76. IOS Press |
| ISSN: | 0924-6479 |
| Popis: | BACKGROUND: A set of enduring conditions have been reported in the literature involving persistent sexual dysfunction after discontinuation of serotonin reuptake inhibiting antidepressants, 5 alpha-reductase inhibitors and isotretinoin.OBJECTIVE: To develop diagnostic criteria for post-SSRI sexual dysfunction (PSSD), persistent genital arousal disorder (PGAD) following serotonin reuptake inhibitors, post-finasteride syndrome (PFS) and post-retinoid sexual dysfunction (PRSD).METHODS: The original draft was designed using data from two published case series (Hogan et al., 2014 and Healy et al., 2018), which represent the largest public collections of data on these enduring conditions. It was further developed with the involvement of a multidisciplinary panel of experts.RESULTS: A set of criteria were agreed upon for each of the above conditions. Features of PSSD, PFS and PRSD commonly include decreased genital and orgasmic sensation, decreased sexual desire and erectile dysfunction. Ancillary non-sexual symptoms vary depending on the specific condition but can include emotional blunting and cognitive impairment. PGAD presents with an almost mirror image of unwanted sensations of genital arousal or irritability in the absence of sexual desire. A new term, post-SSRI asexuality, is introduced to describe a dampening of sexual interest and pleasure resulting from a pre-natal or pre-teen exposure to a serotonin reuptake inhibitor.CONCLUSIONS: These criteria will help in both clinical and research settings. As with all criteria, they will likely need modification in the light of developments. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |